October 14, 2016 / 11:18 AM / 9 months ago

BRIEF-Bristol-Myers receives positive CHMP opinion for Opdivo

1 Min Read

Oct 14 (Reuters) - Bristol-Myers Squibb Co

* Receives positive CHMP opinion for Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with Brentuximab Vedot

* Says CHMP decision based on overall response rate demonstrated by data from two trials, Checkmate -205 and Checkmate -039

* CHMP recommendation will now be reviewed by European commission Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below